跳至主要内容
临床试验/IRCT20200105046010N94
IRCT20200105046010N94招募中Unknown

Bioequivalence study of Mesalazine 1200 mg sustained release tablet (Intesa 1200mg) manufactured by Tasnim Co. versus originator brand Pentasa 1200mg tablet manufactured by Ferring Pharmaceuticals in fasting condition in healthy volunteers

Tasnim company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
All

入选标准

  • General Health (Liver, Heart, and Kidney)
  • Body Mass Index (18-28)
  • Informed consent
  • Age (18-55 years old)

排除标准

  • History of cardiovascular disease
  • History of liver and kidney disease
  • Alcoholism and Narcoticism
  • History of allergy to Mesalazine

研究者

发起方
Tasnim company

相似试验